Camrelizumab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Resectable NSCLC
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Explorative study, which evaluates the effect of Camrelizumab combined with albumin-bound
paclitaxel and cisplatin in neoadjuvant treatment of resectable non-small-cell lung
carcinoma.